FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000588207> ?p ?o ?g. }

• W2000588207 endingPage "379" @default.
• W2000588207 startingPage "370" @default.
• W2000588207 abstract "Radioimmunotherapy capitalizes on the radiosensitivity of non-Hodgkin lymphoma (NHL) and the targeted nature of monoclonal antibodies. In an attempt to reverse bone marrow infiltration with B-cells and optimize the biodistribution of Yttrium-90 (⁹⁰Y)-ibritumomab tiuxetan, we conducted a phase I study combining a single course of ⁹⁰Y-ibritumomab tiuxetan after a 4-weekly course of rituximab in relapsed or refractory low-grade or transformed CD20+ B-cell NHLs with <25% marrow involvement. The 0.4 mCi/kg dose was associated with 80% grade-4 cytopenias. Dose escalation was held, and 6 patients were enrolled at a 0.3 mCi/kg cohort. As the 0.3 mCi/kg dose was well tolerated, the 0.4 mCi/kg cohort was expanded to 6 additional patients. In the expansion cohort, grade-4 cytopenia developed in 33%. Further dose escalation was held, and the maximum tolerated dose was determined at 0.4 mCi/kg. With this regimen, marrow involvement decreased in all patients with complete clearance in 50%. The overall response rate was 82%. With a median follow-up of 31.7 months, the median progression-free survival and time to next treatment were 12.3 and 10.9 months, respectively. Although this regimen was associated with a high response rate, the hematologic toxicity was higher than with the standard ⁹⁰Y-ibritumomab tiuxetan regimen." @default.
• W2000588207 created "2016-06-24" @default.
• W2000588207 creator A5012750761 @default.
• W2000588207 creator A5048644166 @default.
• W2000588207 creator A5057254430 @default.
• W2000588207 creator A5059680487 @default.
• W2000588207 creator A5063423721 @default.
• W2000588207 creator A5084679942 @default.
• W2000588207 creator A5089748359 @default.
• W2000588207 creator A5090898520 @default.
• W2000588207 date "2013-06-01" @default.
• W2000588207 modified "2023-10-15" @default.
• W2000588207 title "Phase I Study of a Modified Regimen of 90Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma" @default.
• W2000588207 cites W1881313440 @default.
• W2000588207 cites W1912693401 @default.
• W2000588207 cites W1915689252 @default.
• W2000588207 cites W1995300466 @default.
• W2000588207 cites W2029862675 @default.
• W2000588207 cites W2055585595 @default.
• W2000588207 cites W2069096955 @default.
• W2000588207 cites W2092589754 @default.
• W2000588207 cites W2092966704 @default.
• W2000588207 cites W2099962215 @default.
• W2000588207 cites W2100404595 @default.
• W2000588207 cites W2106294189 @default.
• W2000588207 cites W2107466475 @default.
• W2000588207 cites W2107990794 @default.
• W2000588207 cites W2110646221 @default.
• W2000588207 cites W2111591374 @default.
• W2000588207 cites W2122808912 @default.
• W2000588207 cites W2133201432 @default.
• W2000588207 cites W2141681661 @default.
• W2000588207 cites W2147581636 @default.
• W2000588207 cites W2154643481 @default.
• W2000588207 cites W2164532418 @default.
• W2000588207 cites W2165172574 @default.
• W2000588207 cites W2168750246 @default.
• W2000588207 cites W2169578616 @default.
• W2000588207 cites W2267583049 @default.
• W2000588207 cites W2414597488 @default.
• W2000588207 cites W2116758034 @default.
• W2000588207 doi "https://doi.org/10.1089/cbr.2012.1387" @default.
• W2000588207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23530878" @default.
• W2000588207 hasPublicationYear "2013" @default.
• W2000588207 type Work @default.
• W2000588207 sameAs 2000588207 @default.
• W2000588207 citedByCount "2" @default.
• W2000588207 countsByYear W20005882072014 @default.
• W2000588207 countsByYear W20005882072021 @default.
• W2000588207 crossrefType "journal-article" @default.
• W2000588207 hasAuthorship W2000588207A5012750761 @default.
• W2000588207 hasAuthorship W2000588207A5048644166 @default.
• W2000588207 hasAuthorship W2000588207A5057254430 @default.
• W2000588207 hasAuthorship W2000588207A5059680487 @default.
• W2000588207 hasAuthorship W2000588207A5063423721 @default.
• W2000588207 hasAuthorship W2000588207A5084679942 @default.
• W2000588207 hasAuthorship W2000588207A5089748359 @default.
• W2000588207 hasAuthorship W2000588207A5090898520 @default.
• W2000588207 hasConcept C121332964 @default.
• W2000588207 hasConcept C126322002 @default.
• W2000588207 hasConcept C142424586 @default.
• W2000588207 hasConcept C143998085 @default.
• W2000588207 hasConcept C159654299 @default.
• W2000588207 hasConcept C18031839 @default.
• W2000588207 hasConcept C203014093 @default.
• W2000588207 hasConcept C2776146153 @default.
• W2000588207 hasConcept C2777058707 @default.
• W2000588207 hasConcept C2778515704 @default.
• W2000588207 hasConcept C2779338263 @default.
• W2000588207 hasConcept C2780007613 @default.
• W2000588207 hasConcept C2780366003 @default.
• W2000588207 hasConcept C2780653079 @default.
• W2000588207 hasConcept C2781413609 @default.
• W2000588207 hasConcept C2989005 @default.
• W2000588207 hasConcept C542903549 @default.
• W2000588207 hasConcept C71924100 @default.
• W2000588207 hasConcept C72563966 @default.
• W2000588207 hasConcept C87355193 @default.
• W2000588207 hasConceptScore W2000588207C121332964 @default.
• W2000588207 hasConceptScore W2000588207C126322002 @default.
• W2000588207 hasConceptScore W2000588207C142424586 @default.
• W2000588207 hasConceptScore W2000588207C143998085 @default.
• W2000588207 hasConceptScore W2000588207C159654299 @default.
• W2000588207 hasConceptScore W2000588207C18031839 @default.
• W2000588207 hasConceptScore W2000588207C203014093 @default.
• W2000588207 hasConceptScore W2000588207C2776146153 @default.
• W2000588207 hasConceptScore W2000588207C2777058707 @default.
• W2000588207 hasConceptScore W2000588207C2778515704 @default.
• W2000588207 hasConceptScore W2000588207C2779338263 @default.
• W2000588207 hasConceptScore W2000588207C2780007613 @default.
• W2000588207 hasConceptScore W2000588207C2780366003 @default.
• W2000588207 hasConceptScore W2000588207C2780653079 @default.
• W2000588207 hasConceptScore W2000588207C2781413609 @default.
• W2000588207 hasConceptScore W2000588207C2989005 @default.
• W2000588207 hasConceptScore W2000588207C542903549 @default.
• W2000588207 hasConceptScore W2000588207C71924100 @default.
• W2000588207 hasConceptScore W2000588207C72563966 @default.
• W2000588207 hasConceptScore W2000588207C87355193 @default.

• next